Barbara Spitzer
Overview
Explore the profile of Barbara Spitzer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1664
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Farouk Sait S, Kernan N, Klein E, Spitzer B, Fein Levy C, Fish J, et al.
Pediatr Blood Cancer
. 2024 Sep;
71(11):e31297.
PMID: 39217426
Background: The prognosis for patients with central nervous system (CNS) retinoblastoma (RB) (trilateral or stage 4b metastatic RB) treated with high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT) remains poor....
2.
Kernan N, Klein E, Mauguen A, Torok-Castanza J, Prockop S, Scaradavou A, et al.
Transplant Cell Ther
. 2024 Apr;
30(7):692.e1-692.e12.
PMID: 38643958
The clinical value of serial routine bone marrow aspirates (rBMAs) in the first year after allogeneic hematopoietic cell transplantation (alloHCT) to detect or predict relapse of acute leukemia (AL) and...
3.
Major-Monfried H, Hosszu K, McAvoy D, Vallone A, Shukla N, Gillio A, et al.
Cytotherapy
. 2024 Mar;
26(5):466-471.
PMID: 38430078
Background Aims: Daratumumab, a human IgG monoclonal antibody targeting CD38, is a promising treatment for pediatric patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). We describe a case...
4.
Lakkaraja M, Mauguen A, Boulad F, Cancio M, Curran K, Harris A, et al.
Cytotherapy
. 2024 Feb;
26(4):351-359.
PMID: 38349310
Background Aims: Traditional weight-based dosing of rabbit anti-thymocyte globulin (rATG) used in allogeneic hematopoietic cell transplantation (HCT) to prevent graft-versus-host disease (GVHD) and graft rejection leads to variable exposures. High...
5.
Kunvarjee B, Siver M, Mathew S, Steiger S, Lee Y, Spitzer B
J Pediatr Hematol Oncol
. 2024 Jan;
46(2):e143-e146.
PMID: 38237014
Isavuconazonium sulfate (ISA) is a triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis in adults. This single-center, retrospective review of pediatric oncology and stem cell transplant patients...
6.
Stonestrom A, Menghrajani K, Devlin S, Franch-Exposito S, Ptashkin R, Patel S, et al.
Blood Adv
. 2023 Dec;
8(4):846-856.
PMID: 38147626
Clonal hematopoiesis (CH) identified by somatic gene variants with variant allele fraction (VAF) ≥ 2% is associated with an increased risk of hematologic malignancy. However, CH defined by a broader...
7.
Zhou Y, Smith J, Keerthi D, Li C, Sun Y, Mothi S, et al.
Blood Adv
. 2023 Nov;
8(3):686-698.
PMID: 37991991
Serial prognostic evaluation after allogeneic hematopoietic cell transplantation (allo-HCT) might help identify patients at high risk of lethal organ dysfunction. Current prediction algorithms based on models that do not incorporate...
8.
Satty A, Klein E, Mauguen A, Kunvarjee B, Boelens J, Cancio M, et al.
Bone Marrow Transplant
. 2023 Sep;
59(1):23-33.
PMID: 37773270
The only curative approach for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) arising in patients with Fanconi anemia (FA) is allogeneic hematopoietic stem cell transplantation (HCT); however, HCT approaches...
9.
Tamari R, Scordo M, Kunvarjee B, Proli A, Lin A, Flynn J, et al.
Blood Adv
. 2023 Jun;
7(18):5225-5233.
PMID: 37379285
Busulfan is an alkylating drug routinely used in conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT). A myeloablative conditioning regimen, including busulfan, is commonly used in patients undergoing T-cell depletion...
10.
Shahid S, Ceglia N, Le Luduec J, McPherson A, Spitzer B, Kontopoulos T, et al.
Blood Adv
. 2023 Jun;
7(17):5069-5081.
PMID: 37327118
Although allogeneic hematopoietic cell transplant (allo-HCT) is curative for high-risk pediatric acute myeloid leukemia (AML), disease relapse remains the primary cause of posttransplant mortality. To identify pressures imposed by allo-HCT...